HIV/AIDS Topics IAS 2011: HIV Treatment In Primary Infection: 48 Week Course Modestly Delays CD4 Drop
- Details
- Category: Primary/Acute HIV
- Published on Friday, 12 August 2011 00:00
- Written by Keith Alcorn
A 48-week course of antiretroviral treatment started within six months of becoming infected modestly delays the need for lifelong treatment, reported Sarah Fidler of Imperial College, London, at the 6th International AIDS Society Conference (IAS 2011) in Rome.
IAS 2011: Poor CD4 Cell Recovery after Starting HIV Treatment Should Be a Cause For Concern
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 09 August 2011 00:00
- Written by Michael Carter
Patients whose CD4 cell count does not recover despite achieving virologic control with HIV therapy require continued medical attention, results of a large European study presented to the recent International AIDS Society conference (IAS 2011) in Rome show.
Can Cannabis Reduce HIV Disease Progression?
- Details
- Category: Alternative & Complementary Therapy
- Published on Tuesday, 31 May 2011 03:10
- Written by Liz Highleyman
THC, the main psychoactive component in marijuana, was associated with decreased viral load and lower risk of death in monkeys infected with a virus related to HIV. 
IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.
5 Drugs No Better than 3 for Treatment of Primary HIV Infection
- Details
- Category: Primary/Acute HIV
- Published on Tuesday, 17 May 2011 06:11
- Written by Liz Highleyman
An intensive antiretroviral therapy (ART) regimen consisting of 5 drugs from 4 different classes did not lead to better outcomes after 1 year than a standard 3-drug regimen started during acute or early HIV infection, according to study data presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) last week in Boston.
Web Design and Development by